Aisling Capital Management as of Sept. 30, 2021
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 21 positions in its portfolio as reported in the September 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 56.7 | $284M | 6.1M | 46.87 | |
| Monte Rosa Therapeutics (GLUE) | 6.5 | $33M | 1.5M | 22.28 | |
| Nuvation Bio Com Cl A (NUVB) | 5.0 | $25M | 2.5M | 9.94 | |
| Harmony Biosciences Hldgs In (HRMY) | 4.5 | $23M | 593k | 38.33 | |
| Elevation Oncology (ELEV) | 4.4 | $22M | 2.8M | 7.79 | |
| Syndax Pharmaceuticals (SNDX) | 3.9 | $20M | 1.0M | 19.11 | |
| Aeglea Biotherapeutics | 2.7 | $13M | 1.7M | 7.95 | |
| Aclaris Therapeutics (ACRS) | 2.3 | $11M | 635k | 18.00 | |
| Biomea Fusion (BMEA) | 1.9 | $9.6M | 799k | 11.97 | |
| Talaris Therapeutics | 1.8 | $9.3M | 683k | 13.56 | |
| Poseida Therapeutics I (PSTX) | 1.5 | $7.6M | 1.0M | 7.29 | |
| Verona Pharma Sponsored Ads (VRNA) | 1.5 | $7.3M | 1.3M | 5.48 | |
| Spruce Biosciences (SPRB) | 1.4 | $7.2M | 1.2M | 6.01 | |
| Reneo Pharmaceuticals (RPHM) | 1.3 | $6.6M | 886k | 7.45 | |
| Avrobio Ord (AVRO) | 1.1 | $5.6M | 1.0M | 5.58 | |
| Marker Therapeutics Ord | 1.1 | $5.3M | 3.1M | 1.69 | |
| Obseva Sa | 0.9 | $4.3M | 1.4M | 3.11 | |
| Atreca Cl A Com (BCEL) | 0.5 | $2.4M | 388k | 6.23 | |
| Viracta Therapeutics (VIRX) | 0.5 | $2.3M | 289k | 8.02 | |
| Zosano Pharma Corporation Com New | 0.4 | $2.0M | 2.7M | 0.72 | |
| Nabriva Therapeutics SHS | 0.0 | $227k | 191k | 1.19 |
